ArticleEmerging microbes & infections2023
CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients.
Article in Emerging microbes & infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- CRIPSR-Cas for hepatitis virus: a systematic review and meta-analysis of diagnostic test accuracy studies.Frontiers in microbiology · 2025Pooled it
- Development and application of a real-time VPCR method for ultra-fast quantitative analysis and Visual Detection of HBV-DNA.Journal of clinical microbiology · 2026Article
- Rapid visual detection of Mycoplasma gallisepticum by combining recombinase-aided amplification with lateral-flow dipstick assay.Poultry science · 2026Article
- CRISPR-Cas13a/Cas12a Assisted Dual Portable and Visualized HDV and HBV Detection.Journal of medical virology · 2026Article
- A toehold-triggered switchable three-way junction protective nanoprobe for RNase H-assisted HBV rcDNA detection.Journal of nanobiotechnology · 2026Article
- Nanoparticle-based biosensor integrated with CRISPR/Cas12b platform for sensitive and visual identification of hepatitis B virus pregenomic RNA in chronic hepatitis B patients.BMC microbiology · 2026Article
- Advances in Rapid Nucleic Acid Diagnostics for Hepatitis B and C Viruses: A Comprehensive Review.Reviews in medical virology · 2026Review
- CRISPR-based diagnostics for infectious diseases: mechanisms, advancements and clinical transformation prospects.Frontiers in cellular and infection microbiology · 2026Review
- CRISPR-based point-of-care diagnostics for viral hepatitis: from molecular design to clinical implementation.Frontiers in bioengineering and biotechnology · 2026Review
- Advances in Novel Detection Technologies for Occult Hepatitis B Virus Infection: Building an Ultra-Sensitive Barrier for Transfusion Safety.Microorganisms · 2025Review
- Integrating CRISPR/Cas technology with clinical trials: Principles, progress and challenges.Asian journal of pharmaceutical sciences · 2025Review
- A direct multiplex isothermal amplification-reverse dot blot hybridization system for β-thalassemia diagnosis.Annals of hematology · 2025Article
- An extraction-free, lyophilized one-pot RAA-CRISPR assay for point-of-care testing ofJournal of clinical microbiology · 2025Article
- An ultrasensitive sensing strategy based on CRISPR/Cas13a and T7 RNA polymerase amplification for detection of extracellular vesicles.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Article
- Therapeutic and preventive treatment on outcomes of hepatitis B virus induced chronic liver disease with a cost-effectiveness analysis.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- An ELISA-like sensitive and visual detection system targetingJournal of clinical microbiology · 2025Article
- Advances in locally administered nucleic acid therapeutics.Bioactive materials · 2025Review
- Integrated Device for Cancer Nucleic Acid Biomarker Detection at Body Temperature.Micromachines · 2025Article
- Development of a dual-target RAA-LFD assay for point-of-care and visual detection ofFrontiers in veterinary science · 2025Article
- Transfusion-transmitted occult hepatitis B virus infection: current understanding, challenges, and its implication in blood safety.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsThe WHO declared to eliminate hepatitis B virus (HBV) by 2030. However, an increasing number of patients are presenting with low-level viremia (LLV) with the widespread use of antiviral medications. The diagnostic efficiency and coverage area of HBV infection are low. Hence, this study intended to drive the HBV infection detection to effectively adaptable for any small to medium-sized laboratory or field survey.
methodsWe established, optimized, and evaluated a colloidal gold test strip for detection of HBV DNA based on CRISPR/Cas13a combined with recombinase-aided amplification (RAA) technology. Furthermore, 180 HBV-infected patients (including patients with different viral loads, LLV patients and dynamic plasma samples of patients on antiviral therapy) were enrolled for clinical validation.
resultsThe strip detection of HBV DNA was established based on RAA-CRISPR-Cas13a technology with a sensitivity of 10
conclusionsWe develop rapid and portable RAA-CRISPR/Cas13a-based strip of HBV DNA detection for LLV patients. This study provides a visual and faster alternative to current PCR-based diagnosis for HBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.